Portfolio Alerts Watch List Cart

HDFC Pharma and Healthcare Fund(IDCW)

Ticker: mf15570
Decent 68/100

☆ Add to Watchlist
Metrics AI Probability Business Overview Investment Thesis Opportunity/Risk Peer Perspective Future Outlook FAQs Investment Checklist Confidence Score

More Options

H
HDFC Pharma and Healthcare Fund(IDCW Reinvest)
Score 68/100 Decent
The fund shows decent potential with strong fundamentals in the pharma sector, but investors should be cautious of execution risks.
View details
S
SBI Income Plus Arbitrage Active FOF(IDCW)
Score 48/100 Decent
The fund shows potential but is hindered by inconsistent growth and moderate profitability metrics. Caution is advised.
View details
S
SBI Income Plus Arbitrage Active FOF(IDCW Payout)
Score 66/100 Decent
The fund shows decent potential but lacks strong growth drivers and consistency in profitability.
View details
L
LIC MF Banking & PSU Fund(W-IDCW)
Score 68/100 Decent
The LIC MF Banking & PSU Fund shows decent potential with stable growth prospects, but investors should be cautious of execution risks and governance issues.
View details
L
LIC MF Banking & PSU Fund(M-IDCW)
Score 68/100 Decent
The LIC MF Banking & PSU Fund shows decent potential with stable growth and profitability metrics, but some risks in governance and execution need to be monitored.
View details
L
LIC MF Banking & PSU Fund(DD-IDCW)
Score 68/100 Decent
The LIC MF Banking & PSU Fund shows decent potential with stable growth prospects, but investors should be cautious of execution risks and liquidity issues.
View details
B
Bandhan Large Cap Fund(IDCW Reinvest)
Score 68/100 Decent
The fund shows decent potential with some growth opportunities, but risks related to execution and liquidity should be monitored.
View details
B
Bandhan Large Cap Fund(IDCW)
Score 48/100 Decent
The Bandhan Large Cap Fund shows potential with decent growth and profitability metrics, but some risks in governance and execution need to be monitored.
View details
F
Franklin India Technology Fund(IDCW)
Score 68/100 Decent
The fund shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
F
Franklin India Technology Fund(IDCW Payout)
Score 68/100 Decent
The fund shows decent potential for growth with manageable risks, making it a reasonable investment option.
View details
K
Kotak Special Opportunities Fund(IDCW)
Score 68/100 Decent
The Kotak Special Opportunities Fund shows decent potential with consistent growth and profitability metrics, but some valuation concerns and execution risks should be monitored.
View details
K
Kotak Special Opportunities Fund(IDCW Payout)
Score 72/100 Decent
The Kotak Special Opportunities Fund shows decent potential with moderate growth and profitability metrics, but faces challenges in valuation and execution risks.
View details
M
Mirae Asset Balanced Advantage Fund(IDCW)
Score 66/100 Decent
The fund shows decent potential with a balanced approach to risk and growth, but investors should remain cautious of execution risks.
View details
B
Bank of India Small Cap Fund(IDCW)
Score 48/100 Risky
The Bank of India Small Cap Fund presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
K
Kotak Multi Asset Omni FOF(IDCW Payout)
Score 72/100 Decent
The Kotak Multi Asset Omni FOF shows decent potential with moderate growth and profitability metrics, but faces challenges in valuation and execution risks.
View details
K
Kotak Multi Asset Omni FOF(IDCW)
Score 72/100 Decent
The Kotak Multi Asset Omni FOF shows decent potential but carries some risks that investors should consider.
View details

Business Overview

HDFC Pharma and Healthcare Fund (IDCW) is a dedicated mutual fund that focuses on investments in the pharmaceutical and healthcare sectors. It is ideal for investors looking to capitalize on the growth potential of India's booming healthcare industry. This fund aims to provide long-term capital appreciation by investing in a diversified portfolio of healthcare-related companies. With a professional management team and a strategic approach, it offers a robust option for those seeking to enhance their investment portfolio with a focus on health and wellness.

  • Focuses on pharmaceutical and healthcare sectors
  • Ideal for long-term capital appreciation
  • Diversified portfolio of healthcare companies
  • Managed by experienced professionals
  • Capitalizes on India's growing healthcare market

Investment Thesis

HDFC Pharma and Healthcare Fund stands out due to its strong promoter credibility and robust management. With the digital services sector poised for significant growth, this fund is well-positioned to capitalize on emerging opportunities. Additionally, its attractive valuation compared to peers makes it an appealing choice for investors seeking exposure in the healthcare sector.

  • Strong backing from HDFC Group enhances credibility and trust.
  • Significant growth potential in the digital healthcare services market.
  • Attractive valuation compared to industry peers, ensuring good entry points.
  • Diversified portfolio reduces risk while targeting high-growth segments.
  • Experienced fund management team with a proven track record.

Opportunity vs Risk

Opportunities
  • Growing healthcare sector in India
  • Strong demand for pharmaceuticals
  • Potential for high returns
  • Government support for healthcare
  • Diversification in investment portfolio
Risks ⚠️
  • Regulatory changes impacting operations
  • Market volatility affecting returns
  • Competition from other funds
  • Economic downturns impacting healthcare
  • Currency fluctuations affecting investments

Peer Perspective

HDFC Pharma and Healthcare Fund trades at a slight premium compared to peers like SBI Healthcare Opportunities Fund and ICICI Prudential Pharma Fund. A sustained improvement in margin stability could trigger a rerating.
📊 Stock Investment Checklist (100 Points)
HDFC Pharma and Healthcare Fund(IDCW) • Updated: 2025-10-01 02:58:46
  • 10
    Business
    High
    Pharma sector shows promise with increasing demand and innovation.
  • 10
    Growth
    High
    Consistent revenue growth driven by healthcare needs.
  • 10
    Profitability
    High
    Healthy ROE and OCF, but net profit margins are moderate.
  • 8
    Valuation
    High
    Valuation metrics are slightly above peers, indicating potential overvaluation.
  • 7
    Balance
    High
    Strong balance sheet with manageable debt levels.
  • 6
    Governance
    Good
    Promoter holding is stable, but some concerns over pledging.
  • 5
    Drivers
    Good
    Growth drivers are present, but execution risks remain.
  • 5
    Technicals
    Good
    Market sentiment is mixed with moderate liquidity.
Final Score & Verdict
Score 68 / 100 • Decent
The fund shows decent potential in the pharma sector with consistent growth, but faces valuation concerns and execution risks.